AI-extracted from the 10-Q filed 2026-10-23 — Q3 FY2026 (quarter ended September 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Quest Diagnostics' Q3 2026 net revenues rose 10.0% to $3,097M on 14.5% requisition volume growth, partly offset by a 4.2% decline in revenue per requisition, while operating income grew 24.2% to $479M.
Biggest Revenue Drivers
DIS business$3,035M+10.2% YoY
Principally driven by organic growth of 10.1%; volume up 14.5%, partly offset by revenue per requisition down 4.2% from business mix tied to Corewell Health and Fresenius Medical Care.
DS businesses$62M+2.3% YoY
Principally consistent with the prior year period; includes risk assessment services and healthcare IT businesses.
Biggest Revenue Drivers
Total revenue: $3.10B+10.0% YoY
DIS business$3,035M+10.2% YoY
Principally driven by organic growth of 10.1%; volume up 14.5%, partly offset by revenue per requisition down 4.2% from business mix tied to Corewell Health and Fresenius Medical Care.
DS businesses$62M+2.3% YoY
Principally consistent with the prior year period; includes risk assessment services and healthcare IT businesses.
Largest Expense Items
Cost of services$2,055M+10.1% YoY
Primarily higher compensation costs and, to a lesser extent, higher supplies expense reflecting testing volumes, partially offset by Invigorate program savings.
Selling, general and administrative$523M+4.3% YoY
Primarily higher compensation costs and, to a lesser extent, spend for Project Nova order-to-cash modernization.
Amortization of intangible assets$37M-4.1% YoY
Principally consistent with the prior year period.
Margins: Operating income rose to 15.5% of net revenues from 13.7% a year earlier, as cost of services and SG&A grew slower than revenue. Diluted EPS was $2.78 versus $2.16.
Watch Items from the Filing
Revenue per requisition declined 4.2% due to business mix from new Corewell Health and Fresenius Medical Care relationships with more routine tests; excluding these impacts it rose 1.7%.
Days sales outstanding rose to 51 days from 47 days a year earlier, primarily from a shift in payer mix toward client payers.
Client payers represented 33% of Q3 net revenue versus 31% a year earlier, while healthcare insurers were 37%.
Pending settlement of AMCA data security incident class actions and state attorney general investigation; reserves for legal matters were $32 million at September 30, 2026.
Contingent consideration liability rose to $103 million from $96 million, with a $7 million fair-value loss recognized for the nine months.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
13 transactions in DGX reported by 8 members of Congress under the STOCK Act, most recent trade Nov 3, 2025. Reported transactions, not recommendations.
About QUEST DIAGNOSTICS INC (DGX): stock profile, AI score and financials
QUEST DIAGNOSTICS INC (DGX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DGX at 70.1/100 on a composite quality score built from its SEC filings, placing it at rank #221 of 2,925 stocks — the top 10% of the AI-ranked universe. DGX scores in the top quartile across revenue scale (87.6), earnings quality (80.3), balance sheet strength (75.6). Based on the latest XBRL financial filings (Q3 2026), QUEST DIAGNOSTICS INC reports quarterly revenue of $3.1B, net income of $312.0M, an operating margin of 15.5%. Top institutional holders of DGX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. DGX trades on the NYSE exchange and files with the SEC under CIK 1022079. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for QUEST DIAGNOSTICS INC directly from SEC EDGAR.